767 related articles for article (PubMed ID: 30086741)
1. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
[TBL] [Abstract][Full Text] [Related]
2. Corosolic acid attenuates platelet-derived growth factor signaling in macrophages and smooth muscle cells of pulmonary arterial hypertension.
Yamamura A; Fujiwara M; Kawade A; Amano T; Hossain A; Nayeem MJ; Kondo R; Suzuki Y; Inoue Y; Hayashi H; Suzuki S; Sato M; Yamamura H
Eur J Pharmacol; 2024 Jun; 973():176564. PubMed ID: 38614383
[TBL] [Abstract][Full Text] [Related]
3. Let-7a-transfected mesenchymal stem cells ameliorate monocrotaline-induced pulmonary hypertension by suppressing pulmonary artery smooth muscle cell growth through STAT3-BMPR2 signaling.
Cheng G; Wang X; Li Y; He L
Stem Cell Res Ther; 2017 Feb; 8(1):34. PubMed ID: 28187784
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin/NFAT Signaling Modulates Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Apoptosis in Monocrotaline-Induced Pulmonary Arterial Hypertension Rats.
He RL; Wu ZJ; Liu XR; Gui LX; Wang RX; Lin MJ
Cell Physiol Biochem; 2018; 49(1):172-189. PubMed ID: 30134231
[TBL] [Abstract][Full Text] [Related]
5. Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction.
Peng LY; Yu M; Yang MX; Liu P; Zhou H; Huang W; Kong H; Xie WP
Am J Hypertens; 2020 Aug; 33(8):775-783. PubMed ID: 32301965
[TBL] [Abstract][Full Text] [Related]
6. Isoquercitrin protects against pulmonary hypertension via inhibiting PASMCs proliferation.
Zhang Y; Cui Y; Deng W; Wang H; Qin W; Huang C; Li C; Zhang J; Guo Y; Wu D; Guo H
Clin Exp Pharmacol Physiol; 2017 Mar; 44(3):362-370. PubMed ID: 27873355
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension.
Chen X; Yu X; Lian G; Tang H; Yan Y; Gao G; Huang B; Luo L; Xie L
Biomed Pharmacother; 2024 May; 174():116505. PubMed ID: 38574614
[TBL] [Abstract][Full Text] [Related]
8. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
9. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M
Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839
[TBL] [Abstract][Full Text] [Related]
11. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
12. Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.
Kurahara LH; Hiraishi K; Yamamura A; Zhang Y; Abe K; Yahiro E; Aoki M; Koga K; Yokomise H; Go T; Ishikawa K; Bo Z; Kishi H; Kobayashi S; Aoki-Shoi N; Toru S; Inoue R; Hirano K
J Mol Cell Cardiol; 2020 Nov; 148():50-62. PubMed ID: 32889002
[TBL] [Abstract][Full Text] [Related]
13. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Notch3 prevents monocrotaline-induced pulmonary arterial hypertension.
Zhang Y; Xie X; Zhu Y; Liu L; Feng W; Pan Y; Zhai C; Ke R; Li S; Song Y; Fan Y; Fan F; Wang X; Li F; Li M
Exp Lung Res; 2015; 41(8):435-43. PubMed ID: 26317171
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.
Paffett ML; Lucas SN; Campen MJ
Vascul Pharmacol; 2012; 56(1-2):64-73. PubMed ID: 22146233
[TBL] [Abstract][Full Text] [Related]
17. Caffeic Acid Phenethyl Ester Rescues Pulmonary Arterial Hypertension through the Inhibition of AKT/ERK-Dependent PDGF/HIF-1α In Vitro and In Vivo.
Cheng CC; Chi PL; Shen MC; Shu CW; Wann SR; Liu CP; Tseng CJ; Huang WC
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909527
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
[TBL] [Abstract][Full Text] [Related]
19. Regulatory effects of Prohibitin 1 on proliferation and apoptosis of pulmonary arterial smooth muscle cells in monocrotaline-induced PAH rats.
Cao YY; Ba HX; Li Y; Tang SY; Luo ZQ; Li XH
Life Sci; 2020 Jun; 250():117548. PubMed ID: 32173312
[TBL] [Abstract][Full Text] [Related]
20. Fluoxetine protects against monocrotaline-induced pulmonary arterial remodeling by inhibition of hypoxia-inducible factor-1α and vascular endothelial growth factor.
Han DD; Wang Y; Zhang XH; Liu JR; Wang HL
Can J Physiol Pharmacol; 2012 Apr; 90(4):445-54. PubMed ID: 22448962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]